Adjuvanted Vaccine to Prevent Respiratory Syncytial Virus in Adults Ages 60 Years and Older.

MYALGIA; RISK assessment; RESPIRATORY infections; PEPTIDE vaccines; VACCINE effectiveness; FATIGUE (Physiology); HEADACHE; RESPIRATORY syncytial virus infections; GLYCOPROTEINS; SURGICAL complications; VIRAL vaccines; PAIN; JOINT pain; DISEASE risk factors; DISEASE complications; MIDDLE age; OLD age

Respiratory syncytial virus (RSV) is a prevalent cause of acute lower respiratory tract illness that disproportionately affects older adults, young children, and infants, which can lead to hospitalizations and death. The health impact on the elderly and infants accentuates the need for effective preventive strategies. Arexvy is the first approved vaccine to prevent lower respiratory tract illness caused by RSV in older adults ages 60 and older. It contains recombinant respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation. Arexvy offers approximately 83% protection in adults and appears to maintain effectiveness for up to two RSV seasons. The vaccine was generally well tolerated in clinical trials, with the most frequently observed and reported adverse events being mild to moderate injection site pain, fatigue, myalgia, headache, and arthralgia. This article includes a description of Arexvy, the target population, contraindications, side effects, and clinical implications when considering the use of this vaccine. Respiratory syncytial virus can pose a high risk for severe lower respiratory tract illness in adults ages 60 years and older; Arexvy, a newly approved vaccine, can help reduce this risk. [ABSTRACT FROM AUTHOR]

Copyright of Nursing for Women's Health is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)